Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02447627 · ClinicalTrials.gov registry record
Study of Methodologies to Measure Blood Flow and Oxygenation in Adults With Sickle Cell Disease
A clinical trial, sponsored by Bioverativ Therapeutics.
- Completed
- Registry status
- 38
- Enrollment target
NCT02447627: Completed study, sponsored by Bioverativ Therapeutics.
NCT02447627 is a clinical trial that has completed, run by Bioverativ Therapeutics. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02447627 has completed, sponsored by Bioverativ Therapeutics.
- COMPLETED
- Registry status
- 38 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether imaging techniques, such as magnetic resonance imaging (MRI), near infrared spectroscopy (NIRS), laser speckle contrast imaging (LSCI), and optical imaging (OI), can detect differences in blood flow and oxygen levels in different organ systems of participants with sickle cell disease (SCD). Differences in blood flow and oxygen levels detected by these techniques will be evaluated to determine their utility as biomarkers of clinical disease pathophysiology.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2015-06 |
| Est. Completion | 2016-10 |
What the finished NCT02447627 record still lists
NCT02447627 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 38 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02447627 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02447627 about?
NCT02447627 is a clinical study titled "Study of Methodologies to Measure Blood Flow and Oxygenation in Adults With Sickle Cell Disease". The purpose of the study is to determine whether imaging techniques, such as magnetic resonance imaging (MRI), near infrared spectroscopy (NIRS), laser speckle contrast imaging (LSCI), and optical imaging (OI), can detect differences in blood flow and oxygen levels in different organ systems of part...
What is the current status of trial NCT02447627?
This trial is currently completed. The enrollment target is 38 participants. The study started on 2015-06. Estimated completion is 2016-10.
Who is sponsoring clinical trial NCT02447627?
This trial is sponsored by Bioverativ Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia